Skip to content

CEO video statement. 2024 Q3-results

Another strong quarter  

For the CRO business, performance was strong with organic revenue growth year-over-year of 25% for the quarter and 31% for the first nine months. Within the Discovery & Partnerships (D&P) business, significant progress was made across several R&D projects, not least the advancement of our anti-obesity Amylin program where topline results from the Phase 1 Single Ascending Dose (SAD) study are expected to be released in November. 

Watch this video with our CEO Henrik Blou where he covers all the main developments in just about 3-4 minutes. 

Contacts at Gubra
Media: Sofia Pitt Boserup, [email protected], +45 4188 9586
Investors: Kristian Borbos, [email protected], +45 3080 8035 

Share this page

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

[email protected]
+45 3152 ­2650

Back To Top